Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29911019 | 1.00 | MAPT (0.74) | MAPTGAATP53ALDH1A1MEN1 | |
| SCHEMBL17552232 | 0.86 | MAPT (0.62) | MAPTGAATP53ALDH1A1MEN1 | |
| SCHEMBL29911020 | 0.86 | MAPT (0.62) | MAPTGAATP53ALDH1A1MEN1 | |
| SCHEMBL26798492 | 0.86 | MAPT (0.78) | MAPTGAATP53ALDH1A1MEN1 | |
| SCHEMBL26798504 | 0.86 | MAPT (0.62) | MAPTGAATP53ALDH1A1MEN1 | |
| SCHEMBL17552214 | 0.85 | MAPT (0.64) | MAPTGAATP53ALDH1A1MEN1 | |
| SCHEMBL29831079 | 0.85 | MAPT (0.64) | MAPTGAATP53ALDH1A1MEN1 | |
| SCHEMBL29911131 | 0.84 | MAPT (0.74) | MAPTGAATP53ALDH1A1MEN1 | |
| SCHEMBL17552189 | 0.84 | MAPT (0.74) | MAPTGAATP53ALDH1A1MEN1 | |
| SCHEMBL29831327 | 0.84 | MAPT (0.70) | MAPTGAATP53ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-01-18 | — | — | US | disclosed |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4037685-B1 | QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE | NEURODON CORP (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230285382-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2023-09-14 | — | — | US | disclosed |
| CN-116744928-A | Quinolines modulating SERCA and their use for treating diseases | 神经元公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220016108-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2022-01-20 | — | — | US | disclosed |
| US-20200347038-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2020-11-05 | — | — | US | disclosed |
| US-10772881-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION | 2020-09-15 | — | — | US | disclosed |
| US-20190151303-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2019-05-23 | — | — | US | disclosed |
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | EIGER BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2016032569-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | CELLADON CORPORATION (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285382-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885GAA 94/4885TP53 3732/4885 |
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | ATP2A1, ATP2A3, ATP2A2 | MAPT 1538/4885GAA 36/4885TP53 3254/4885 |
| US-10772881-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | MAPT 1307/4885GAA 65/4885TP53 3639/4885 |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885GAA 94/4885TP53 3732/4885 |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885GAA 94/4885TP53 3732/4885 |
| US-20190151303-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MAPT 1307/4885GAA 65/4885TP53 3639/4885 |
| US-20220016108-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885GAA 94/4885TP53 3732/4885 |
| US-20200347038-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885GAA 94/4885TP53 3732/4885 |
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MAPT 1228/4885GAA 94/4885TP53 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.